Zegalogue is owned by Zealand Pharma.
Zegalogue contains Dasiglucagon Hydrochloride.
Zegalogue has a total of 1 drug patent out of which 0 drug patents have expired.
Zegalogue was authorised for market use on 22 March, 2021.
Zegalogue is available in solution;subcutaneous dosage forms.
Drug patent challenges can be filed against Zegalogue from March, 2025.
The generics of Zegalogue are possible to be released after 03 February, 2035.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US10442847||ZEALAND PHARMA||Glucagon analogues|| |
(12 years from now)
|New Chemical Entity Exclusivity (NCE)||Mar 22, 2026|
NCE-1 date: March, 2025
Market Authorisation Date: 22 March, 2021
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic